An extension trial to evaluate the long-term safety and efficacy of navenibart (STAR-0215) in preventing attacks in people with type 1 and type 2 HAE.

At a glance
Trial Overview
Trial Details
Interventions
Trial History
References

Trial Profile

An extension trial to evaluate the long-term safety and efficacy of navenibart (STAR-0215) in preventing attacks in people with type 1 and type 2 HAE.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 18 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Navenibart (Primary)
Indications Hereditary angioedema
Focus Registrational; Therapeutic Use
Acronyms ORBIT-EXPANSE

Most Recent Events

18 Mar 2025 New trial record
11 Mar 2025 According to an Astria Therapeutics media release, the navenibart Phase 3 program consists of the ALPHA-ORBIT Phase 3 trial and ORBIT-EXPANSE long-term trial, are designed to support registration globally.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com